SavedAdd your journal

Journals / İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi / 2021 / Cilt: 11 - Sayı: 3

Neuroblastoma-targeted Anticancer Drug Delivery

Nöroblastomda Hedeflenmiş Anti Kanser İlaç Taşınımı

Safiye AKTAŞ
Hatice Nur OLGUN
Aylin EROL
Özde Elif GÖKBAYRAK
Pages
219–225
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Here, we review new therapeutic approaches that would help to treat NB.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Neuroblastoma (NB) is the most common solid tumor in pediatric cases.
📊
Key Findings & Data:NB accounts for about 8% of malignancies in patients younger than 15 years, and since 50% of newly diagnosed cases metastasize to regional lymph nodes, bone marrow, bone, liver, and skin, the disease is usually diagnosed in its late stages.
💡
Conclusion & Impact:Here, we review new therapeutic approaches that would help to treat NB.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Neuroblastoma (NB) is the most common solid tumor in pediatric cases. NB accounts for about 8% of malignancies in patients younger than 15 years, and since 50% of newly diagnosed cases metastasize to regional lymph nodes, bone marrow, bone, liver, and skin, the disease is usually diagnosed in its late stages. Overexpression of N-MYC, which is characterized by poor prognosis in NB, changes the progression of the disease and the course of the treatment. Targeting these pathways may be a treatment option in NB, since the mTOR and AURKA pathways interact with N-MYC and directly cause protein stabilization. The widespread use of conventional chemotherapeutics has some limitations associated with their common side effects and the bioavailability of the drugs. New therapeutic approaches have focused on nanoparticle (NP) -based therapies, and chemoimmunoagents in the form of many NPs are being tried in NB. Here, we review new therapeutic approaches that would help to treat NB.

Özet

Nöroblastom (NB), pediatrik olgularda en yaygın görülen solid tümördür. NB, 15 yaşından genç pediatrik hastaların %8’inde malignansi göstermekle birlikte, tanı konanlarda %50’sinde bölgesel lenf noduna, kemik iliğine, kemiğe, karaciğere ve deriye metastaz görülmektedir. Hastalık genelde geç evrelerde tanı almaktadır. N-MYC’nin aşırı ekspresyonu NB’de kötü prognoz ile karakterize olmuştur ve tedavi ve hastalığın ilerleyişini değiştirmektedir. mTOR ve AURKA yolakları N-MYC ile ilişkili olarak protein stabilizasyonuna neden olduğundan dolayı, NB’de bu yolakları hedeflemek yeni bir tedavi stratejisi oluşturabilir. Günümüzde kullanım alanı geniş olan konvansiyonel kemoterapötik ilaçlar, bilinen yaygın yan etkileri ve ilacın biyoyararlanımı gibi sebeplerden dolayı bazı sınırlayıcı faktörlere sahiptir. Yeni terapötik ajanlar, nanopartikül (NP) bazlı tedavilere yönelmiştir ve NP formunda birçok kemoimmünoajan NB’de denenmektedir. Bu makalede NB tedavisinde kullanılan yeni yaklaşımları özetledik.

🔖

Cite This Article

AKTAŞ, S., OLGUN, H. N., EROL, A., GÖKBAYRAK, Ö. E. (2022). Neuroblastoma-targeted Anticancer Drug Delivery. İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi, Cilt: 11 - Sayı: 3, 219–225. https://ajindex.com/articles/557618

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ayers D. Current Challenges in the Management of Neuroblastoma. Elsevier Inc.; 2019.
  2. Trigg RM, Shaw JA, Turner SD. Opportunities and challenges of circulating biomarkers in neuroblastoma. Open Biol. 2019;9(5).
  3. Avendaño C, Menéndez JC. Medicinal chemistry of anticancer drugs. Med Chem Anticancer Drugs. 2008;35(7):4376-7
  4. Faisal A, Vaughan L, Bavetsias V, et al. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in Vivo. Mol Cancer Ther. 2011;10(11):2115-23.
  5. Yang Y, Ding L, Zhou Q, et al. Silencing of AURKA augments the antitumor efficacy of the AURKA inhibitor MLN8237 on neuroblastoma cells. Cancer Cell Int. 2020;20(1):1-16.
  6. Greengard E. Molecularly targeted therapy for neuroblastoma. Children. 2018;5(10):142.
  7. Felgenhauer J, Tomino L, Selich-Anderson J, Bopp E, Shah N. Dual BRD4 and AURKA Inhibition is Synergistic against MYCN-amplified and nonamplified Neuroblastoma. biorxiv. 2018;10(4):276840.
  8. Zafar A, Wang W, Liu G, et al. Molecular targeting therapies for neuroblastoma: Progress and challenges. Med Res Rev. 2021;41(2):961-1021.
  9. Mei H, Wang Y, Lin Z, Tong Q. The mTOR signaling pathway in pediatric neuroblastoma. Pediatr Hematol Oncol. 2013;30(7):605-15.
  10. Morgenstern DA, Irwin MS. Current and future strategies for treatment of relapsed neuroblastoma. Neuroblastoma Mol Mech Ther Interv. Published online 2019:263-81.
  11. Pastor ER, Mousa SA. Current management of neuroblastoma and future direction. Crit Rev Oncol Hematol. 2019;138(November 2018):38-43.
  12. Mu W, Chu Q, Liu Y, Zhang N. A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy. NanoMicro Lett. 2020;12(1).
  13. Heo MB, Kim SY, Yun WS, Lim YT. Sequential delivery of an anticancer drug and combined immunomodulatory nanoparticles for efficient chemoimmunotherapy. Int J Nanomedicine. 2015;10(October):5981-93.
  14. Dang Y, Guan J. Nanoparticle-based drug delivery systems for cancer therapy. Smart Mater